The aim of this study has been to assess the clinical presentation and biochemical profile of lipoid proteinosis within a defined pedigree. Glycoprotein analysis was compared to normal values in an attempt to define a biochemical phenotype. Six affected family members were identified with variable degrees of disease expression. The most likely mode of inheritance is autosomal recessive due to consanguinity. Routine laboratory investigations were normal in all family members tested. The total content of mucopolysaccharides, sialic acid and hexosamine in biopsed tissue was significantly lower than normal. Our findings demonstrate that a defect in glycoprotein synthesis, possibly enzymatic, may be the cause of lipid proteinosis and its protean clinical manifestations.

Keywords:
Lipoid proteinosis, Mucopolysaccharides, Sialic acid, Hexosamine
1.
Urbach E, Wiethe C: Lipoids cutis and mucosae. Virchows Arch Pathol Anat Physiol Klin Med 1929;273:285–319.
2.
Blodi FC, Whiney RD, Hendrides CA: Lipoid proteinosis (Urbach-Wiethe) involving the lids. Trans Am Acad Ophthalmol Othorhinol 1960;58:155–166.
3.
Caplan RM: Visceral involvement in lipoid proteinosis. Arch Dermatol 1967;95:149–155.
4.
François J, Bacskullin J, Follmann P: Manifestations oculaires du syndrome d’Urbach-Wiethe. Ophthalmologica 1968;155:433–448.
5.
Feiler-Ofry V, Lewy A, Regenbogen L, Hanau D, Bat-Miriam Katznelson M, Godel V: Lipoid proteinosis (Urbach-Wiethe syndrome). Br J Ophthalmol 1979;63:694–698.
6.
Johnson LH, Hepler RS: Corectopia and lipoid proteinosis. Br J Ophthalmol 1989;73:394–396.
7.
Irkeç M, Orhan M, Orhan D, Durgun B, Can C: Dry eye syndrome associated with Urbach-Wiethe disease. J Pediatr Ophthalmol Strabismus 1996;33:265–268.
8.
Katzenellenbogen I, Ungar H: Lipoid proteinosis (reinvestigation of a case previously reported by Urbach and Wiethe in 1929). Dermatologica 1957;115:23–28.
9.
Brocheriou C, Kuffer R, Laufer J, Verola O: Cutaneous-mucous hyalinosis (Urbach-Wiethe disease): Histologic and ultrastructural study of a case. Ann Pathol 1984;4:297–303.
10.
Jensen AD, Khodadoust A, Emey JM: Lipoid proteinosis. Arch Ophthalmol 1972;88:273–277.
11.
Paller AS: Histology of lipoid proteinosis. JAMA 1994;272:771.
12.
Federico A, Di Benedetta A: Glycoprotein changes during the development of human brain. J Neurochem 1978;31:797–800.
13.
Warren L: The thiobarbituric acid assay of sialic acids. J Biol Chem 1959;234:1971–1975.
14.
Boas NF: Method for the determination of hexosamines in tissues. J Biol Chem 1953;204:553–563.
15.
Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275.
16.
Rosenthal AR, Duke JR: Lipoid proteinosis: Case report of direct lineal transmission. Am J Ophthalmol 1967;64:1120–1125.
17.
Gordon H, Gordon W, Botha V: Lipoid proteinosis in an inbred Namaqualand community. Lancet 1969;i:1033–1035.
18.
Feldmann FF, Newmann BA: Lipoid proteinosis (Urbach-Wiethe). Arch Dermatol 1957;75:760–765.
19.
Rosenthal G, Lifshitz T, Monos T, Kachco L, Argov S: Carbon dioxide laser treatment for lipoid proteinosis (Urbach-Wiethe syndrome) involving the eyelids. Br J Ophthalmol 1997;81:253.
20.
Mauri C: Malattie del sangue e degli organi emopoietici; in Teodori U (ed): Trattao di Patologia Medica. Rom, Soc Editrice Universo, 1977, pp 963–1332.
21.
McKusick VA (ed): Heritable Disorders of Connective Tissue. St. Louis, Mosby, 1979, pp 145–147.
22.
Brimacombe JS, Stacey M: Mucopolysaccharides in disease; in Sober HA (ed): Handbook of Biochemistry. The Chemical Rubber Co. Cleveland, CRC Press, 1968; pp 187–231.
23.
Barondes SH (ed): The Neurosciences, 2nd Study Programme. New York, Rockefeller, University Press, 1970, pp 747–760.
24.
Tranel D, Hyman BT: Neuropsychological correlates of bilateral amygdala damage. Arch Neurol 1990;47:349–355.
25.
Kelly JE, Simpson MT, Jonathan D, Hollway TE: Lipid proteinosis: Urbach-Wiethe disease. Br J Anaesthesia 1989;63:609–611.
© 1999 S. Karger AG, Basel
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.